Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Galectin-3 plays a key pathogenic role in cardiac hypertrophy and heart failure. The present study aimed to investigate the effects of galectin-3 on cardiomyopathy – related factors and cardiac contractility in a rat model of cirrhotic cardiomyopathy. Methods: Rats were divided into two sets, one for a functional study, the other for cardiac contractile-related protein evaluation. There were four groups in each set: sham operated and sham plus N-acetyllactosamine (N-Lac, a galectin-3 inhibitor; 5 mg/kg); bile duct ligated (BDL) and BDL plus N-Lac. Four weeks after surgery, ventricular level of galectin-3, collagen I and III ratio, tumor necrosis factor alpha (TNFα), and brain natriuretic peptide (BNP) were measured either by Western blots or immunohistochemistry or enzyme-linked immunosorbent assay. Blood pressure was measured by polygraph recorder. Cardiomyocyte contractility was measured by inverted microscopy. Results: Galectin-3 and collagen I/III ratio were significantly increased in cirrhotic hearts. TNFα and BNP were significantly increased in BDL serum and heart compared with sham controls. Galectin-3 inhibitor significantly decreased galectin-3, TNFα, and BNP in cirrhotic hearts but not in sham controls. N-Lac also significantly improved the blood pressure, and systolic and diastolic cardiomyocyte contractility in cirrhotic rats but had no effect on sham controls. Conclusion: Increased galectin-3 in the cirrhotic heart significantly inhibited contractility via TNFα. Inhibition of galectin-3 decreased the cardiac content of TNFα and BNP and reversed the decreased blood pressure and depressed contractility in the cirrhotic heart. Galectin-3 appears to play a pathogenic role in cirrhotic cardiomyopathy.
Abstract
Background/Aims: Galectin-3 plays a key pathogenic role in cardiac hypertrophy and heart failure. The present study aimed to investigate the effects of galectin-3 on cardiomyopathy – related factors and cardiac contractility in a rat model of cirrhotic cardiomyopathy. Methods: Rats were divided into two sets, one for a functional study, the other for cardiac contractile-related protein evaluation. There were four groups in each set: sham operated and sham plus N-acetyllactosamine (N-Lac, a galectin-3 inhibitor; 5 mg/kg); bile duct ligated (BDL) and BDL plus N-Lac. Four weeks after surgery, ventricular level of galectin-3, collagen I and III ratio, tumor necrosis factor alpha (TNFα), and brain natriuretic peptide (BNP) were measured either by Western blots or immunohistochemistry or enzyme-linked immunosorbent assay. Blood pressure was measured by polygraph recorder. Cardiomyocyte contractility was measured by inverted microscopy. Results: Galectin-3 and collagen I/III ratio were significantly increased in cirrhotic hearts. TNFα and BNP were significantly increased in BDL serum and heart compared with sham controls. Galectin-3 inhibitor significantly decreased galectin-3, TNFα, and BNP in cirrhotic hearts but not in sham controls. N-Lac also significantly improved the blood pressure, and systolic and diastolic cardiomyocyte contractility in cirrhotic rats but had no effect on sham controls. Conclusion: Increased galectin-3 in the cirrhotic heart significantly inhibited contractility via TNFα. Inhibition of galectin-3 decreased the cardiac content of TNFα and BNP and reversed the decreased blood pressure and depressed contractility in the cirrhotic heart. Galectin-3 appears to play a pathogenic role in cirrhotic cardiomyopathy.
참고문헌 (31)
- Liu H, "Advances in cirrhotic cardiomyopathy", Curr Opin Gastroenterol, 37, pp.187~193 (2021)
- Chahal D, "Review article : comprehensive analysis of cirrhotic cardiomyopathy", Aliment Pharmacol Ther, 53, pp.985~998 (2021)
- Gaskari SA, "Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoids", J Hepatol, 62, pp.1272~1277 (2015)
- Wanninger J, "Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function", Cytokine, 55, pp.435~440 (2011)
- Farr M, "Recent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates : advanced echo imaging, cardiac biomarkers, and advanced heart failure therapies", Clin Med Insights Cardiol, 8(Suppl 1), pp.67~74 (2014)
- van Kimmenade RR, "Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure", J Am Coll Cardiol, 48, pp.1217~1224 (2006)
- Sun RR, "Biomarkers and heart disease", Eur Rev Med Pharmacol Sci, 18, pp.2927~2935 (2014)
- de Boer RA, "Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction", Ann Med, 43, pp.60~68 (2011)
- Shah RV, "Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure", Eur J Heart Fail, 12, pp.826~832 (2010)
- Weir RA, "Galectin-3 and cardiac function in survivors of acute myocardial infarction", Circ Heart Fail, 6, pp.492~498 (2013)
- Honar H, "Impaired myosin isoform shift and calcium transients contribute to cellular pathogenesis of rat cirrhotic cardiomyopathy", Liver Int, 40, pp.2808~2819 (2020)
- Liu L, "Protective effects of erythropoietin on cirrhotic cardiomyopathy in rats", Dig Liver Dis, 44, pp.1012~1017 (2012)
- Glenn TK, "Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats", J Hepatol, 55, pp.1249~1255 (2011)
- Liu H, "Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy", Liver Int, 28, pp.640~648 (2008)
- Barondes SH, "Galectins. Structure and function of a large family of animal lectins", J Biol Chem, 269, pp.20807~20810 (1994)
- Suarez G, "Heart failure and galectin 3", Ann Transl Med, 2, pp.86~ (2014)
- Liu FT, "Galectins : regulators of acute and chronic inflammation", Ann N Y Acad Sci, 1183, pp.158~182 (2010)
- Fortuna-Costa A, "Extracellular galectin-3 in tumor progression and metastasis", Front Oncol, 4, pp.138~ (2014)
- Jiang JX, "Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo", Am J Physiol Gastrointest Liver Physiol, 302, pp.G439~G446 (2012)
- Yu L, "Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis", Circ Heart Fail, 6, pp.107~117 (2013)
- Sharma UC, "Galectin-3 marks activated macrophages in failureprone hypertrophied hearts and contributes to cardiac dysfunction", Circulation, 110, pp.3121~3128 (2004)
- Souza BSF, "Association of cardiac galectin-3 expression, myocarditis, and fibrosis in chronic chagas disease cardiomyopathy", Am J Pathol, 187, pp.1134~1146 (2017)
- Liu H, "Cirrhotic cardiomyopathy : implications for liver transplantation", Liver Transpl, 23, pp.826~835 (2017)
- de Boer RA, "Galectin-3 : a novel mediator of heart failure development and progression", Eur J Heart Fail, 11, pp.811~817 (2009)
- Hrynchyshyn N, "Galectin-3 : a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure", Arch Cardiovasc Dis, 106, pp.541~546 (2013)
- Schroeder JT, "Epithelial cell-associated galectin-3 activates human dendritic cell subtypes for pro-inflammatory cytokines", Front Immunol, 11, pp.524826~ (2020)
- Yang YY, "Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice : interaction between TNFalpha and endocannabinoids", J Hepatol, 53, pp.298~306 (2010)
- Liu H, "Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats", Gastroenterology, 118, pp.937~944 (2000)
- Trippel TD, "The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction : results from the DIAST-CHF study", ESC Heart Fail, 8, pp.829~841 (2021)
- Yoon KT, "Cirrhotic cardiomyopathy", Curr Gastroenterol Rep, 22, pp.45~ (2020)
- Limas CJ, "Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain", Circulation, 49, pp.754~760 (1974)